Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.

The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.

Viatris (NASDAQ:VTRS) reported strong Q2 2025 results, with total revenues of $3.58 billion, down 6% year-over-year but exceeding expectations. The company's adjusted EPS reached $0.62, while adjusted EBITDA was $1.1 billion. Despite challenges, Viatris demonstrated resilience across its global business segments.

Key highlights include positive results from five Phase 3 clinical trials and significant capital returns to shareholders totaling $630 million year-to-date, including $350 million in share buybacks. The company reiterated its 2025 financial guidance, expecting to perform in the top half of the range for total revenues and adjusted EPS.

Regional performance showed strength in Greater China with 9% growth, while other markets faced some headwinds. The company continues to advance its late-stage pipeline and maintains its commitment to strategic growth initiatives for 2026 and beyond.

Viatris (NASDAQ:VTRS) has announced its latest quarterly dividend declaration. The company's Board of Directors has declared a dividend of $0.12 per share on August 4, 2025. The dividend will be paid on September 15, 2025, to shareholders who hold Viatris stock as of the close of business on August 22, 2025.

Viatris (NASDAQ: VTRS) has appointed David Simmons to its Board of Directors, bringing significant pharmaceutical industry and executive leadership experience. Simmons' notable career includes serving as CEO of Caliber Holdings Corporation, Operating Partner at Hellman & Friedman, and Chairman and CEO of PPD, Inc., where he led a 30,000-employee workforce and tripled the company's enterprise value, culminating in its $17.4 billion sale to Thermo Fisher Scientific in 2021.

Previously at Pfizer, Simmons served as President and General Manager of both the Established Products Unit and Emerging Markets division, managing 20,000 employees and 30% of Pfizer's global sales. His board experience includes positions at Cordis, Curia Global, Launch Therapeutics, Medline Industries, and Owens & Minor.

["Appointment of highly experienced pharmaceutical industry executive with proven leadership track record", "Direct experience with Viatris' established products portfolio from Pfizer tenure", "Extensive global commercial and R&D expertise", "Strong capital markets background including IPO and M&A experience"]

Viatris (Nasdaq: VTRS) announced the presentation of five scientific abstracts at the upcoming PAINWeek 2025 conference, showcasing data from its Phase 3 program for a novel fast-acting meloxicam formulation (MR-107A-02) in treating moderate-to-severe acute surgical pain.

The presentations, scheduled for September 2-5, 2025, in Las Vegas, will feature results from two pivotal studies in herniorrhaphy and bunionectomy surgery models. The data includes pharmacokinetics, efficacy, safety, and opioid use reduction findings. Four abstracts will have live presentations on September 4, while one will be a poster-only presentation.

Viatris (Nasdaq: VTRS) reported that its Phase 3 study of pimecrolimus 0.3% (MR-139) ophthalmic ointment for blepharitis failed to meet its primary endpoint of complete debris resolution after six weeks of twice-daily treatment.

The company is now evaluating next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Despite this setback, Viatris highlighted recent successes with other pipeline products, including positive Phase 3 results from the LYNX-2 trial of MR-142 for keratorefractive conditions and the VEGA-3 Trial of MR-141 for presbyopia.

Viatris (NASDAQ:VTRS) announced positive top-line results from its VEGA-3 Phase 3 trial for MR-141, a treatment for presbyopia. The randomized, placebo-controlled study involving 545 patients met its primary and all secondary endpoints, demonstrating significant improvement in near vision without compromising distance vision.

The trial showed statistically significant results (p<0.0001) in achieving ≥3-line gain in binocular distance-corrected near visual acuity. Patients reported significant functional benefits and satisfaction with near vision improvements, particularly in dim lighting conditions. The safety profile remained consistent with previous trials, with no treatment-related serious adverse events.

Viatris plans to submit an FDA application in H2 2025 for MR-141, targeting a condition that affects approximately 90% of U.S. adults over 45.

Viatris (NASDAQ: VTRS) has announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a webcast at 8:30 a.m. ET on the same day where executives will discuss the quarterly performance. Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website for later viewing.

Viatris (NASDAQ: VTRS) announced positive Phase 3 LYNX-2 trial results for MR-142, a potential first-in-class treatment for night driving impairment in keratorefractive patients. The trial, involving 199 patients under FDA Special Protocol Assessment, met its primary endpoint with significantly more patients achieving ≥15-letter gain in mesopic low contrast visual acuity compared to placebo. MR-142 demonstrated patient-reported benefits in reducing difficulties with oncoming headlights and glare while driving. The drug showed no tachyphylaxis over 6 weeks and maintained a consistent safety profile. The FDA granted Fast Track designation for MR-142, potentially accelerating its development for treating chronic night driving impairment. A second pivotal study, LYNX-3, is expected to begin soon with results anticipated in H1 2026.